
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is a promising biopharmaceutical company utilizing precision medicine to develop anti-cancer treatments, with a current focus on stenoparib for ovarian cancer. Despite potential risks such as balance sheet issues and competition, Allarity has a strong pipeline and the potential to bring valuable treatments to patients with high unmet medical needs, making for a positive long-term outlook for investors.
Bears say
Allarity Therapeutics is a clinical-stage pharmaceutical company with a negative outlook due to its minimal revenue generation, high cash burn rate, and lack of guidance or consensus estimates. Its main drug, Stenoparib, is still in the development phase, and the clinical data has not shown enough promise to justify the large market potential for ovarian cancer and the highly competitive PARP inhibitor market. The company's high risk and lack of strong results make it an unattractive investment opportunity.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares